Azitra (AZTR) Shares Outstanding (Weighted Average) (2022 - 2026)
Azitra (AZTR) reported Shares Outstanding (Weighted Average) of $100000.0 for Q1 2026, down 94.94% on a YoY basis from $2.0 million in Q1 2025, and down 97.95% quarter-over-quarter from $4.9 million in Q4 2025.
Azitra (AZTR) Shares Outstanding (Weighted Average) (2022 - 2026) Analysis & Trends
Azitra has reported Shares Outstanding (Weighted Average) for 5 years, with the latest figure at $100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 94.94% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $100000.0 (down 94.94% YoY), and the FY2025 full-year result was $4.9 million, up 28.78% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $100000.0, down from $4.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $20.2 million in Q1 2024, with the low at $71622.0 in Q2 2023.
- Historically, Shares Outstanding (Weighted Average) has averaged $3.5 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) surged 3266.66% — and 2026, when it plunged 94.94%.
- Azitra's Shares Outstanding (Weighted Average) stood at $1.1 million in 2022, then plunged by 78.22% to $229866.0 in 2023, then surged by 148.48% to $571162.0 in 2024, then soared by 753.27% to $4.9 million in 2025, then tumbled by 97.95% to $100000.0 in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $100000.0 (Q1 2026), $4.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 4.87 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 14.73 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 571,162.00 |
| Sep 30, 2024 | 5.81 Mn |
| Jun 30, 2024 | 960,146.00 |
| Mar 31, 2024 | 20.18 Mn |
| Dec 31, 2023 | 229,866.00 |
| Sep 30, 2023 | 172,704.00 |
| Jun 30, 2023 | 71,622.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 1.06 Mn |